major
outbreak
happen
republ
korea
viru
infect
majorli
observ
adult
although
affect
age
peopl
within
short
time
viru
affect
total
number
individu
die
mortal
rate
worldwid
saudi
arabia
alon
last
two
decad
extens
studi
these
human
coronavirus
especi
sarsand
merscov
led
understand
coronavirus
biolog
also
driven
discoveri
new
therapeut
case
futur
outbreak
review
focu
recent
develop
inhibitor
target
coronavirus
coronavirus
member
two
subfamili
coronavirina
torovirina
famili
coronavirida
turn
compris
order
nidoviral
fig
coronavirina
subfamili
classifi
four
main
genera
acoronaviru
bcoronaviru
gcoronaviru
dcoronaviru
base
intern
committe
taxonomi
virus
fig
belong
acoronaviru
sarscov
merscov
bcoronavirus
infect
mammal
gcoronaviru
dcoronaviru
infect
bird
also
infect
mammal
base
current
sequenc
databas
discov
human
cov
anim
origin
sarscov
merscov
consid
origin
bat
like
origin
rodent
electron
microscop
coronavirus
envelop
singlestrand
positivesens
rna
viru
largest
genom
size
rang
approxim
found
date
genom
rna
act
messeng
rna
mrna
play
import
role
initi
rna
synthesi
infecti
cycl
templat
replic
transcript
substrat
packag
progeni
viru
cov
twothird
genom
encod
replicas
polyprotein
compris
two
overlap
open
read
frame
orf
orf
process
viral
proteas
cleav
nonstructur
protein
involv
genom
transcript
replic
terminu
encod
cov
canon
set
four
structur
protein
includ
nucleocapsid
n
protein
basic
rnabind
protein
ii
spike
protein
type
glycoprotein
ii
membran
protein
span
membran
iii
envelop
protein
e
highli
hydrophob
protein
cover
entir
structur
coronaviru
fig
accessori
protein
import
virion
assembl
may
also
addit
link
suppress
host
immun
respons
facilit
viral
replic
replic
coronaviru
begin
bind
spike
protein
cell
surfac
molecul
host
receptor
recognit
import
initi
viru
entri
host
cell
therebi
play
major
role
tissu
host
speci
tropism
virus
receptor
use
human
cov
known
see
tabl
aminopeptidas
n
oacetyl
sialic
acid
angiotensinconvert
enzym
sarscov
dipeptidyl
peptidas
merscov
apart
cov
may
also
enter
cell
help
proteas
exampl
role
cathepsin
l
link
sarsand
merscov
entri
transmembran
proteas
serin
airway
trypsinlik
proteas
could
activ
protein
viru
entri
cell
membran
sarscov
infect
upon
entri
viral
particl
uncod
readi
translat
orf
polyprotein
amino
acid
amino
acid
process
proteas
proteas
papainlik
proteas
plpro
subsequ
polyprotein
cleav
least
nonstructur
protein
nsp
assembl
form
replicationtranscript
complex
aid
replicas
fulllength
posit
strand
genom
rna
transcrib
form
fulllength
negativestrand
templat
synthesi
new
genom
rna
mrna
transcrib
translat
produc
structur
accessori
protein
interrupt
replic
process
would
becom
potenti
molecular
target
develop
therapeut
although
human
cov
real
threat
human
popul
numer
research
mainli
focus
sarsand
merscov
infect
respons
sever
ill
compar
cov
numer
agent
identifi
inhibit
entri
andor
replic
sarsand
merscov
cell
cultur
anim
model
due
high
morbid
mortal
rate
sar
mer
sever
antivir
drug
immunomodul
use
empir
evalu
uncontrol
trial
see
repres
exampl
fig
ribavirin
wide
use
treat
varieti
viral
infect
sar
clinic
outcom
antivir
intervent
signific
effect
patient
hand
patient
receiv
ribavirin
lopinavir
see
fig
ritonavir
corticosteroid
lower
acut
respiratori
distress
syndrom
ard
death
rate
receiv
ribavirin
corticosteroid
combin
therapi
use
interferon
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
system
corticosteroid
alon
uncontrol
studi
use
corticosteroid
methylprednisolon
fig
therapeut
intervent
sar
patient
associ
increas
mortal
rate
adjust
ci
howev
dissemin
fungal
infect
avascular
osteonecrosi
occur
follow
prolong
system
corticosteroid
therapi
random
placebocontrol
studi
show
plasma
sarscov
rna
level
week
ill
higher
patient
given
hydrocortison
n
given
normal
salin
n
earli
phase
ill
suggest
earli
use
puls
methylprednisolon
might
prolong
viremia
case
patient
mer
combin
ritonavir
interferon
interferon
result
signific
effect
clinic
outcom
casecontrol
studi
show
significantli
improv
surviv
treat
control
group
respect
p
day
day
retrospect
analys
show
combin
ritonavir
interferon
signific
effect
clinic
outcom
anoth
studi
combin
ribavirin
ritonavir
interferon
resolv
viremia
within
day
commenc
treatment
patient
sever
mer
patient
sever
mer
treat
methylprednisolon
without
antivir
interferon
favor
respons
typic
drugdiscoveri
program
develop
new
potent
antivir
agent
obtain
approv
clinic
use
take
year
effect
vaccin
drug
approv
potent
inhibitor
clinic
develop
treat
coronaviru
infectionsto
speed
discoveri
potenti
potenti
antivir
therapeut
use
patient
sar
mer
infect
treatment
option
human
pathogen
coronavirus
two
gener
approach
employ
especi
sarsand
merscov
link
sever
diseas
cov
first
approach
repurpos
broadli
act
antivir
drug
use
viral
infect
indic
drug
obviou
benefit
alreadi
avail
known
pharmacokinet
pharmacodynam
properti
solubl
metabol
stabil
side
effect
dose
regimen
drug
includ
interferon
b
g
ribavirin
inhibitor
cyclophilin
discov
use
approach
combin
therapi
interferon
ribavirin
show
best
result
treat
merscov
infect
also
differ
drug
repurpos
coronavirus
infect
wwwdrugdiscoverytodaycom
type
interferon
includ
employ
manag
patient
merscov
infect
recent
sever
research
group
report
discoveri
antivir
drug
use
drug
repurposingapproach
shen
et
al
report
broadspectrum
inhibitor
human
coronavirus
see
tabl
identifi
seven
compound
lycorin
emetin
monensin
sodium
mycophenol
mofetil
mycophenol
acid
phenazopyridin
pyrvinium
pamoat
ht
screen
broadspectrum
inhibitor
accord
strong
inhibit
replic
four
cov
vitro
lowmicromolar
concentr
seven
broadspectrum
inhibitor
suppress
replic
cov
dosedepend
manner
low
ec
valu
although
cytotox
concentr
compound
high
inhibit
phenazopyridin
pyrvinium
pamoat
monensin
sodium
display
less
cc
valu
vivo
studi
show
lycorin
protect
mice
lethal
infect
search
potenti
antivir
agent
cov
de
wild
et
al
identifi
four
drug
chloroquin
chlorpromazin
loperamid
lopinavir
screen
fda
approv
drug
librari
fig
abl
inhibit
replic
merscov
sarscov
well
low
micromolar
rang
suggest
could
use
broad
spectral
antivir
activ
mode
action
inhibit
replic
merscov
dosedepend
manner
ec
mm
inhibit
contribut
blockad
viru
earli
stage
compound
previous
report
effect
antivir
agent
flaviviru
influenza
viru
hiv
ebola
viru
niphahendra
viru
chlorpromazin
anoth
hit
compound
result
screen
inhibit
replic
merscov
ec
mm
chlorpromazin
first
antipsychot
drug
develop
treatment
schizophrenia
mechanist
inhibit
clathrinmedi
endocytosi
also
report
inhibit
replic
hepat
c
viru
hcv
alphaviru
mous
hepat
viru
coronaviru
sarscov
mechanist
studi
chlorpromazin
merscov
indic
inhibit
viru
earli
postentri
stage
suggest
effect
clathrinmedi
endocytosi
sole
antivir
mechan
loperamid
antidiarrh
opioid
receptor
agonist
reduc
intestin
motil
inhibit
replic
merscov
addit
inhibit
two
coronavirus
low
micromolar
rang
mm
lopinavir
antihiv
proteas
inhibitor
also
inhibit
replic
merscov
ec
mm
previous
report
inhibit
sarscov
main
proteas
mpro
therefor
presum
might
also
target
pro
merscov
current
antimerscov
agent
primarili
result
previou
drug
use
sarscov
infect
identifi
potenti
antivir
agent
merscov
shin
et
al
screen
librari
consist
approv
drug
pharmaceut
activ
compound
yield
seri
hit
compound
primarili
categor
antiprotozo
anticanc
antipsychot
found
suppress
earli
stage
merscov
life
cycl
cell
possibl
suppress
sfk
signal
pathway
interestingli
cotreat
saracatinib
gemcitabin
deoxycytidin
analog
commonli
use
treatment
cancer
show
synergist
antivir
effect
minim
cytotox
effect
support
hypothesi
use
combin
therapi
treat
cov
diseas
continu
sever
class
compound
use
indic
identifi
potent
inhibitor
sarsand
merscov
drug
classifi
differ
therapeut
group
neurotransmitt
inhibitor
estrogen
receptor
antagonist
kinas
signal
inhibitor
proteinprocess
inhibitor
inhibitor
lipid
sterol
metabol
inhibitor
dna
synthesi
pair
see
repres
exampl
fig
activ
tabl
antidiarrh
agent
loperamid
agent
lopinavir
abl
inhibit
mersand
sarscov
infect
lowmicromolar
rang
linear
studi
de
wild
et
al
antiparasit
mefloquin
amodiaquin
dihydrochlorid
antibacteri
emetin
dihydrochlorid
hydrat
function
link
coronavirus
gener
show
antivir
activ
cov
cathepsin
import
fusion
step
viru
entri
coronaviru
cathepsin
inhibitor
block
merscov
sarscov
entri
stage
neurotransmitt
inhibitor
triflupromazin
inhibit
sarscov
merscov
addit
neurotransmitt
fluphenazin
promethazin
report
inhibit
merscov
proteinmedi
cellcel
fusion
ic
valu
mm
respect
kinas
signal
pathway
inhibitor
imatinib
mesyl
dasatinib
known
inhibitor
abelson
murin
leukemia
viral
oncogen
pathway
activ
merscov
sarscov
data
suggest
pathway
may
import
viral
replic
inhibitor
pathway
may
potenti
discoveri
antivir
agent
identifi
dna
synthesi
inhibitor
exampl
gemcitabin
hydrochlorid
activ
least
one
coronaviru
suggest
drug
potenti
antivir
therapi
coronavirus
toremifen
citrat
repurpos
variou
class
drug
sarsand
merscov
wwwdrugdiscoverytodaycom
review
keynot
review
estrogen
receptor
antagonist
inhibit
merscov
sarscov
ec
mm
respect
second
approach
anticov
drug
discoveri
involv
de
novo
develop
novel
specif
agent
base
genom
biophys
understand
individu
coronaviru
exampl
includ
sirna
molecul
inhibitor
target
specif
viral
enzym
involv
viral
replic
cycl
mab
target
host
receptor
inhibitor
host
cellular
proteas
inhibitor
viru
endocytosi
host
cell
human
human
mab
target
subunit
rbd
antivir
peptid
target
subunit
despit
high
speci
divers
cov
share
key
genom
element
essenti
design
therapeut
agent
larg
replicas
polyprotein
process
cleav
two
viral
proteas
pl
pro
pro
produc
nonstructur
protein
nsp
rnadepend
rna
polymeras
rdrp
helicas
involv
transcript
replic
viru
numer
enzym
inhibitor
target
protein
shown
anticov
activ
vitro
inhibitor
target
nucleosid
nucleotid
build
block
viral
nucleic
acid
broadspectrum
activ
wide
rang
coronavirus
well
virus
gener
mycophenol
fig
immunosuppress
drug
use
prevent
reject
organ
transplant
inhibit
inosin
monophosph
dehydrogenas
key
ratelimit
enzym
de
novo
purin
synthesi
pathway
convert
inosin
monophosph
guanosin
monophosph
activ
molecul
mycophenol
acid
see
structur
tabl
drug
discoveri
today
volum
number
decemb
exhibit
broadspectrum
vitro
antivir
activ
variou
virus
includ
hepat
b
viru
hbv
hepat
c
viru
hcv
arbovirus
recent
mycophenol
acid
identifi
potenti
antimerscov
drug
highthroughput
screen
approach
potent
antimerscov
activ
vitro
howev
subsequ
studi
nonhuman
primat
model
provid
posit
result
treatment
merscov
infect
common
marmoset
mycophenol
acid
wors
outcom
untreat
anim
proteas
indispens
viral
life
cycl
play
essenti
role
viral
replic
mediat
matur
viral
replicas
therefor
target
proteas
becom
attract
approach
develop
potenti
antivir
drug
proteas
inhibitor
block
replic
coronavirus
cov
includ
caus
agent
mer
sar
infect
papainlik
proteas
pl
pro
proteas
pro
also
known
main
proteas
import
two
proteas
mediat
process
replicas
polyprotein
pl
pro
cystein
proteas
use
thiol
group
cystein
nucleophil
attack
carbonyl
group
scissil
peptid
bond
cleavag
first
three
posit
polyprotein
produc
three
nonstructur
protein
pro
cleav
remain
locat
releas
nonstructur
protein
result
sequenc
motif
recogn
merscov
pl
pro
sarscov
pl
pro
li
xgg
ad
x
lxgg
ak
x
respect
fig
dehaen
et
al
report
novel
librari
fuse
deriv
coronaviru
hel
cell
structureact
relationship
studi
show
compound
display
moder
inhibitori
activ
micromolar
rang
without
alter
normal
cell
morpholog
confluent
hel
cell
cultur
concentr
mm
exampl
compound
see
fig
although
author
claim
inhibitor
could
inhibit
proteas
base
molecular
model
previous
report
inhibitor
could
confirm
experi
et
al
report
broadspectrum
activ
natur
product
silvestrol
fig
specif
inhibitor
deadbox
rna
helicas
merscov
viral
translat
use
dual
luciferas
assay
virusinfect
primari
cell
silvestrol
recent
shown
potent
antivir
activ
ebola
virusinfect
human
macrophag
found
silvestrol
also
potent
nontox
inhibitor
capdepend
viral
mrna
translat
covinfect
human
embryon
lung
fibroblast
cell
found
highli
effect
infect
ec
valu
nm
nm
respect
merscov
potent
antivir
activ
silvestrol
also
confirm
use
peripher
blood
mononuclear
cell
pbmc
second
type
human
primari
cell
mechanist
silvestrol
strongli
inhibit
express
cov
structur
nonstructur
protein
n
format
viral
replic
transcript
complex
also
confirm
silvestrol
found
inhibit
human
rhinoviru
hrv
polioviru
pv
respect
snijder
et
al
report
alisporivir
nonimmunosuppress
cyclosporin
aanalog
structur
shown
inhibit
replic
differ
human
coronavirus
includ
mersand
sarscoronaviru
low
micromolar
concentr
theinvestig
suggest
alisporivir
inhibit
mersand
sarscov
replic
cellcultur
base
screen
assay
reli
rapid
cytopath
effect
cpe
observ
coronavirusinfect
cell
antivir
therapi
p
lpro
import
target
multifunct
protein
involv
proteolyt
deubiquitin
wwwdrugdiscoverytodaycom
deisgyl
isg
interferonstimul
gene
viral
evas
innat
immun
respons
addit
proteolyt
activ
sever
xray
crystallographi
studi
facilit
character
pl
pro
enzym
identif
pl
pro
inhibitor
numer
sarscov
pl
pro
inhibitor
belong
differ
classeshav
identifi
includ
smallmolecul
inhibitor
thiopurin
compound
natur
product
zinc
ion
zinc
conjug
inhibitor
naphthalen
inhibitor
nethylmaleimid
well
immunosuppress
drug
mycophenol
acid
independ
abl
inhibit
proteolyt
activ
deubiquitin
merscov
plpro
tabl
compar
nethylmaleimid
effect
inhibitor
mycophenol
acid
less
effect
inhibitor
merscov
pl
pro
disulfiram
fig
fda
drug
use
alcohol
avers
therapi
drug
report
inhibit
activ
methyltransferas
kinas
ureas
react
cystein
residu
suggest
broadspectrum
characterist
notabl
disulfiram
report
alloster
inhibitor
merscov
pl
pro
suggest
administr
togeth
compound
andor
could
synergist
inhibit
merscov
papainlik
proteas
trifluoromethyl
fig
identifi
select
dual
inhibitor
pl
pro
enzym
merscov
sarscov
highthroughput
screen
molecul
librari
contain
chemic
entiti
mode
action
compound
act
competit
inhibitor
merscov
ic
valu
mm
act
alloster
inhibitor
sarscov
ic
mm
compound
first
synthes
potenti
anticanc
agent
late
earli
compound
use
reactant
design
arrhythmia
antivir
drug
well
compound
set
regul
plant
growth
naphthalen
amid
fig
report
inhibit
merscov
pl
pro
inact
sarscov
pl
pro
suggest
structur
differ
bind
mode
pl
proteas
support
recent
xray
crystal
structur
sarscov
pl
pro
complex
lead
inhibitor
structur
reveal
inhibitor
bind
catalyt
site
sar
cov
pl
pro
loop
appear
prevent
access
substrat
activ
site
therebi
inhibit
enzymat
activ
structur
sequenc
analysi
loop
sarscov
plproand
mer
cov
pl
pro
suggest
differ
key
amino
acid
residu
respons
inhibitor
bind
exampl
respons
inhibitor
bind
sarscov
pl
pro
wherea
mer
cov
pl
pro
find
suggest
make
dual
inhibitor
target
pl
pro
sarsand
merscov
difficult
park
et
al
assess
inhibitori
activ
polyphenol
deriv
b
papyrifera
sarsand
merscov
isol
polyphenol
markedli
inhibit
pl
cov
proteas
sar
mer
ic
valu
compound
though
higher
peptidederiv
inhibitor
still
low
micromolar
rang
particular
isol
compound
pro
cystein
proteas
analog
main
picornaviru
proteas
famili
virus
also
caus
respiratori
ill
broadspectrum
anticov
inhibitor
peptid
deriv
fig
identifi
inhibit
proteolyt
activ
merscov
pro
ic
mmoll
xray
crystal
structur
merscov
pro
inhibitor
confirm
inhibit
pro
similar
mechan
cov
inhibitor
bind
interfac
domain
ii
merscov
pro
ec
mm
peptid
deriv
potent
inhibitor
rhinoviru
pro
michael
acceptor
function
fail
inhibit
sarscov
pro
howev
seri
analog
report
combat
cov
target
pro
screen
peptidomimet
see
fig
contain
michael
acceptor
group
ie
bunsatur
carbonyl
show
moder
anticov
activ
enteroviru
inhibitor
recent
shown
inhibit
merscov
ec
valu
rang
mm
inhibitor
provid
excel
start
point
develop
natur
substrat
mimick
peptidomimet
compound
sarsand
merscov
pro
benzotriazol
deriv
activ
carbonyl
function
display
inhibit
sarscov
pro
merscov
pro
ester
fig
shown
block
replic
sarsand
merscov
pro
could
serv
potenti
lead
futur
drug
develop
anticoronaviru
therapi
pyrazolon
base
neuraminidas
na
inhibitor
fig
report
inhibit
merscov
pro
moder
potenc
rang
mm
pharmacophor
moieti
phenyl
carboxyl
either
suggest
essenti
antivir
activ
dipeptidyl
transit
state
pro
inhibitor
inhibit
activ
merscov
pro
ec
mm
fluoresc
reson
energi
transfer
fret
assay
anoth
pyrrolidinon
base
peptid
well
deriv
display
inhibit
merscov
valu
mm
mm
mm
cell
cultur
kenichi
et
al
report
new
nonpeptid
sarscov
pro
inhibitor
introduc
decahydroisoquinolin
posit
connect
cyclohexyl
group
substratebas
inhibitor
fig
result
compound
fig
show
moder
promis
inhibitori
activ
sarscov
pro
suggest
decahydroisoquinolin
scaffold
could
novel
scaffold
posit
sarscov
pro
inhibit
cocryst
structur
sarscov
pro
decahydroisoquinolin
inhibitor
reveal
scaffold
insert
larg
pocket
occupi
pocket
structur
pro
inhibitor
contain
michael
acceptor
aldehyd
activ
carbonyl
function
group
expect
studi
extend
find
novel
inhibitor
interact
site
reason
nonprim
site
substitu
warhead
combin
decahydroisonolin
design
evalu
sarscov
pro
result
analog
acthrglyoh
compound
fig
instead
origin
acthrval
sequenc
sinc
isopropyl
side
chain
val
direct
outward
sar
pro
interact
sar
pro
val
site
detect
inde
compound
show
time
potent
inhibitori
activ
sar
pro
combin
nonprim
site
substitu
find
indic
expect
addit
interact
sar
pro
also
possibl
new
inhibitor
contain
fusedr
system
hydrophob
scaffold
new
warhead
thioacet
report
matur
sar
proteas
subject
degrad
site
therefor
mutant
proteas
high
activ
stabil
prepar
kenichi
et
al
involv
develop
inhibitor
sar
mutant
proteas
result
compound
develop
ic
valu
nm
howev
due
problem
like
enzymat
digest
peptid
chain
aproton
racem
compound
taken
forward
solv
problem
design
anoth
deriv
fig
serin
backbon
mutant
proteas
compound
fig
show
weak
inhibitori
activ
way
develop
small
molecul
inhibitor
investig
structur
modif
inhibitor
found
isoserin
backbon
could
altern
serin
one
result
analog
fig
show
ic
valu
mm
mutant
proteas
compound
character
microbi
cytotox
activ
howev
show
inhibitori
activ
screen
microbi
cytotox
structur
pro
inhibitor
wwwdrugdiscoverytodaycom
grouta
et
al
report
novel
class
peptidomimet
pro
inhibitor
embodi
piperidin
moieti
inhibitor
design
base
dipeptidyl
aldehyd
bisulfit
adduct
inhibitor
design
fig
clinic
demonstr
efficaci
attach
piperidin
moieti
dipeptidyl
compon
permit
result
hybrid
inhibitor
engag
favor
bind
interact
subsit
enzym
peptidomimet
show
excel
inhibit
merscov
well
sarscov
infect
see
exampl
compound
nonpeptid
sarscov
pro
inhibitor
contain
serin
isoserin
scaffold
helicas
ubiquit
protein
requir
wide
rang
biolog
process
genom
replic
recombin
displac
protein
bound
na
chromatin
remodel
helicas
protein
critic
compon
requir
viru
replic
host
cell
thu
may
serv
feasibl
target
antim
antisar
chemic
therapi
recent
adedeji
et
al
report
small
deriv
see
fig
inhibit
viral
ntpasehelicas
known
nonstructur
protein
sarsand
merscov
antivir
activ
inhibit
merscov
sarscov
replic
ec
valu
mm
mm
respect
signific
cytotox
observ
concentr
mm
far
helicas
inhibitor
approv
antivir
therapi
thu
compound
could
serv
potenti
lead
develop
effect
broadspectrum
anticoronaviru
drug
like
rna
virus
coronavirus
employ
host
cell
membran
assembl
viral
replicas
complex
evolutionari
conserv
strategi
provid
compart
viral
rna
synthesi
crucial
step
coronaviru
life
cycl
antivir
agent
target
membranebound
coronavir
rna
synthesi
import
replic
therefor
repres
novel
attract
target
lundin
et
al
discov
inhibitor
design
fig
target
membranebound
coronavir
rna
synthesi
show
potent
antivir
activ
merscov
infect
remark
efficaci
host
innat
interferon
respons
crucial
control
viral
replic
infect
although
cov
suppress
interferon
respons
immun
evas
remain
dipeptidyl
aldehyd
bisulfit
adduct
inhibitor
replicas
rna
synthesi
inhibitor
wwwdrugdiscoverytodaycom
suscept
interferon
treatment
vitro
interferon
respons
augment
administr
recombin
interferon
interferon
induc
recombin
interferona
interferonb
inhibit
replic
sarscov
merscov
vitro
anim
model
variou
combin
interferona
orb
antivir
ribavirin
andor
lopinavirritonavir
use
treat
patient
sar
mer
overal
combin
treatment
consist
interferon
ribavirin
consist
improv
outcom
appar
discrep
vitro
find
vivo
outcom
may
relat
high
ec
cmax
ratio
drug
delay
symptom
onset
drug
administr
delay
especi
relev
mer
patient
much
shorter
median
time
interv
symptom
onset
death
sar
patient
use
recombin
interferon
lowest
ec
cmaxratio
merscov
among
test
prepar
recombin
interferon
evalu
combin
effect
antivir
clinic
trial
earli
stage
infect
nitazoxanid
fig
anoth
potent
type
interferon
induc
use
human
parasit
infect
synthet
nitrothiazolylsalicylamid
deriv
exhibit
broadspectrum
antivir
activ
rna
dna
virus
includ
canin
cov
influenza
virus
hbv
hcv
hiv
rotaviru
noroviru
flavivirus
evalu
phase
ii
phase
iii
clinic
trial
treatment
hcv
infect
influenza
good
safeti
profil
addit
direct
potenti
interferon
respons
cell
signal
pathway
identifi
potenti
anticov
treatment
target
cyclophilin
interact
sarscov
modul
calcineurin
pathway
import
cellmedi
adapt
immun
respons
calcineurin
inhibitor
cyclosporin
fig
inhibit
broad
rang
cov
vitro
howev
immunosuppress
effect
high
ec
cmax
ratio
standard
therapeut
dosag
limit
clinic
applic
trametinib
selumetinib
everolimu
rapamycin
dasatinib
imatinib
exampl
inhibitor
kinas
signal
pathway
activ
sarscov
merscov
see
repres
exampl
fig
mechan
action
block
erkmapk
andor
pathway
may
block
earli
viral
entri
andor
postentri
event
howev
major
drawback
inhibitor
may
associ
immunopatholog
cov
util
specif
host
factor
viru
entri
replic
specif
monoclon
polyclon
antibodi
peptid
function
inhibitor
target
host
receptor
exampl
mab
inhibit
merscov
cell
entri
vitro
repres
hostbas
anticovir
drug
cov
infect
treatment
sarscov
smallmolecul
entri
inhibitor
n
naae
inhibit
catalyt
activ
sarscov
smediat
cellcel
fusion
vitro
neurotransmitt
inhibitor
includ
chlorpromazin
fluphenazin
promethazin
report
inhibit
cellcel
fusion
moder
level
ec
valu
mm
respect
addit
disrupt
clathrinmedi
endocytosi
inhibit
merscov
hiv
entri
inhibitor
target
fig
could
inhibit
merscov
pseudoviru
infect
cell
interrupt
entri
pseudotyp
merscov
ec
mm
cell
line
cc
mm
cell
mtt
assay
entri
cov
host
cell
via
endosom
andor
cell
surfac
pathway
facilit
host
proteas
cleav
activ
protein
cathepsin
cystein
proteas
involv
endosom
pathway
inhibit
cathepsin
inhibitor
relat
vinyl
sulfon
analog
compound
seem
safe
effect
variou
parasit
infect
anim
model
broadspectrum
activ
envelop
rna
virus
cov
sarscov
merscov
filovirus
ebola
marburg
virus
paramyxovirus
ouabain
bufalin
fig
inhibit
merscov
entri
block
clathrinmedi
endocytosi
dihydrotanshinon
fig
lipophil
compound
show
decim
reduct
mgml
excel
antivir
effect
mgml
reduct
titer
log
log
tcid
ml
use
pseudoviru
express
merscov
spike
protein
biosynthesi
merscov
protein
furin
inhibitor
decanoylrvkrchloromethylketon
decrvkrcmk
fig
mm
lead
decreas
cleav
product
merscov
wt
mutant
recent
small
molecul
discov
character
inhibitor
sarscov
replic
block
viral
entri
three
differ
mechan
compound
act
novel
mechan
action
block
earli
interact
sarss
receptor
sarscov
angiotensinconvert
enzym
ii
compound
act
later
block
cathepsin
l
host
proteas
requir
process
sarss
viral
entri
iii
compound
also
act
later
affect
interact
sarss
enzymat
function
cathepsin
l
prevent
fusion
viral
membran
host
cellular
membran
naphthalen
sulfonamid
deriv
select
clathrin
inhibitor
target
aminotermin
domain
tetradecyltrimethylammonium
bromid
mitmab
dynamin
ii
gtpase
inhibitor
report
inhibit
replic
inhibit
clathrinmedi
entri
importantli
cytotox
effect
observ
test
inhibitor
appli
cell
remain
incessantli
one
import
etiolog
factor
respiratori
tract
diseas
human
recent
found
employ
depend
endocytosi
entri
subsequ
cholesterolbind
deplet
agent
nystatin
fig
methylbcyclodextrin
mbcd
fig
report
inhibit
viru
replic
via
depend
endocytosi
entri
anoth
class
anticov
agent
target
inhibit
cov
entri
carbohydratebind
agent
griffithsin
antivir
protein
origin
isol
red
alga
griffithsia
spp
bind
specif
oligosaccharid
viral
surfac
glycoprotein
hiv
glycoprotein
inhibit
broad
rang
cov
includ
sarscov
vitro
sarscovinfect
mice
optim
deliveri
mode
safeti
profil
agent
human
evalu
altern
increas
number
agent
target
specif
bind
site
function
protein
gener
crystallographi
function
assay
exampl
includ
viroporin
inhibitor
hexamethylen
amilorid
fig
reduc
ion
channel
activ
e
sarscov
compound
fig
bind
distinct
ribonucleotidebind
pocket
ntermin
domain
n
howev
agent
like
exhibit
narrowspectrum
bind
site
function
protein
uniqu
individu
cov
novel
lipophil
thiazolidin
deriv
fig
fig
membranebind
photosensit
produc
singlet
oxygen
molecul
induc
chang
properti
lipid
membran
prevent
fusion
viral
target
cell
membran
exhibit
broadspectrum
activ
numer
envelop
virus
may
activ
cov
addit
abovement
molecul
numer
peptidebas
inhibitor
coronavirus
sever
nucleic
acid
synthesi
inhibitor
broadspectrum
activ
sarscov
merscov
virus
inosin
monophosph
dehydrogenas
impdh
inhibitor
ribavirin
mycophenol
acid
inhibit
import
step
de
novo
synthesi
nucleic
acid
discuss
earlier
mizoribin
anoth
impdh
also
prove
inhibit
synthesi
nucleic
acid
mizoribin
fig
approv
immunosuppress
organ
transplant
limit
advers
side
effect
shown
vitro
activ
hcv
bovin
viral
diarrhea
viru
bvdv
consid
altern
ribavirinifn
combin
treatment
hcv
infect
mizoribin
exert
activ
select
inhibit
inosin
monophosph
synthetas
guanosin
monophosph
synthetas
result
complet
inhibit
guanin
nucleotid
synthesi
without
incorpor
nucleotid
chemotherapeut
gemcitabin
shown
vitro
activ
merscov
sarscov
discuss
earlier
remdesivir
develop
code
fig
antivir
drug
novel
nucleotid
analog
prodrug
develop
gilead
scienc
treatment
ebola
viru
diseas
marburg
viru
infect
though
subsequ
also
found
show
reason
antivir
activ
distantli
relat
virus
respiratori
syncyti
viru
junin
viru
lassa
fever
viru
merscoronaviru
remdesivir
rapidli
push
clinic
trial
due
west
african
ebola
viru
epidem
crisi
eventu
use
least
one
human
patient
despit
earli
develop
stage
time
preliminari
result
promis
use
emerg
set
kivu
ebola
outbreak
along
clinic
trial
vitro
remdesivir
show
potent
antivir
activ
malaysian
bangladesh
genotyp
nipah
viru
reduc
replic
nipah
viru
malaysia
primari
human
lung
microvascular
endotheli
cell
four
order
magnitud
warrant
test
efficaci
remdesivir
nipah
viru
infect
vivo
contrast
control
anim
succumb
infect
remdesivirtr
anim
surviv
lethal
challeng
indic
remdesivir
repres
promis
antivir
treatment
nipah
viru
infect
also
human
coronavirus
util
host
cellular
compon
achiev
variou
physiolog
process
includ
viral
entri
genom
replic
assembl
bud
virion
therebi
result
patholog
damag
host
therefor
interrupt
stage
viral
life
cycl
would
becom
potenti
therapeut
target
develop
antivir
therapi
although
numer
antihuman
coronavir
agent
identifi
variou
approach
specif
treatment
current
avail
hcov
date
one
main
reason
identifi
agent
properli
evalu
vitro
vivo
studi
increas
understand
novel
emerg
coronavirus
accompani
increas
opportun
reason
design
therapeut
importantli
understand
basic
inform
coronaviru
proteas
target
aid
public
health
sarscov
merscov
also
help
advanc
target
new
coronavirus
may
emerg
futur
spite
huge
effort
taken
academia
pharmaceut
industri
coronaviru
proteas
inhibitor
yet
success
market
mm
sm
collect
data
tp
wrote
manuscript
revis
